Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Jillian Swain

Nurse Practitioner Fort Smith, AR Nurse Practitioner

NPI 1528840113 CMS profile 11546323

1501 S Waldron Rd, Fort Smith, AR 72903

Open in the dashboard

General payments

$536

18 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jillian Swain of Fort Smith, AR is reported in the CMS Open Payments database as having received $536 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $536 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jillian Swain
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jillian Swain were reported at $536. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jillian Swain Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $536 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2025
  1. AstraZeneca Pharmaceuticals LP $235 5 payments
  2. AbbVie, Inc. $95 4 payments
  3. UCB, Inc. $66 3 payments
  4. Amgen Inc. $44 2 payments
  5. Pfizer Inc. $43 2 payments
  6. ANI Pharmaceuticals, Inc. $32 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $536 18 payments
Products named General payments · program year 2025
  1. RINVOQ $95 4 payments
  2. AIRSUPRA $91 3 payments
  3. Bimzelx $66 3 payments
  4. Otezla $44 2 payments
  5. XELJANZ $43 2 payments
  6. PURIFIED CORTROPHIN GEL $32 1 payment
  7. SAPHNELO $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

634

Median for Nurse Practitioner: 389

Drug cost

$5,536

Median for Nurse Practitioner: $21,885

Branded share of claims

29.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 63 $1,601
Doxycycline Hyclate Generic 117 $1,030
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 34 $500
Fluticasone Propionate Generic 48 $429
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 42 $377
Azithromycin Generic 82 $376
Cephalexin Generic 44 $372
Methylprednisolone Generic 57 $353
Cefdinir Generic 12 $159
Ciprofloxacin Hcl Generic 18 $119

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$32,038

Of which drugs: $159

Medicare patients

316

Average age 73

Services billed

1,162

219 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 26%
Diabetes 25%
Depression 25%
Chronic kidney disease 22%
Osteoporosis 22%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 93 $64
Injection, ceftriaxone sodium, per 250 mg J0696 Office 17 72 $23
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 96 $7
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 12 15 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record